-

SMAIO: 2026 Financial Calendar

DALLAS & LYON, France--(BUSINESS WIRE)--Regulatory News:

SMAIO (Software, Machines and Adaptive Implants in Orthopaedics – Euronext Growth Paris, ISIN: FR0014005I80 / Ticker: ALSMA), a French-American player specialized in complex spine surgery, offering an integrated pre, intra, and post-operative solution based on a 3D planning software, adaptive implants and related services, today announces its indicative financial calendar for 2026.

Events

Dates

2025 full-year revenue

Tuesday, January 20, 2026

2025 full-year results

Tuesday, April 14, 2026

Revenue for the first quarter of 2026

Tuesday, May 12, 2026

Annual general meeting

Tuesday, June 16, 2026

2026 first-half revenue

Thursday, July 16, 2026

2026 first-half results

Tuesday, October 13, 2026

Revenue for the third quarter of 2026

Thursday, November 12, 2026

This preliminary agenda may be modified. Each publication will be released after market close.

About SMAIO

A precursor in the use of clinical data and imaging of the spine, SMAIO designs global solutions for spine surgery specialists. The Company has recognized expertise thanks to KEOPS, its Big Data management software that has become a global reference with more than 100,000 patient cases documented. SMAIO offers spine surgeons a comprehensive platform, I-Kontrol, incorporating planning, implants and related services, enabling them to treat spinal pathologies in a safe, effective and lasting way. The Company’s open platform deployed in the United States, KEOPS-4ME, is designed to deliver a personalized and data-driven approach to complex spine surgery, enabling SMAIO to partner commercially with major U.S. surgical companies and provide their surgeon clients with patient-specific implants. Based in Dallas (United States) and Lyon (France), SMAIO benefits from the skill and expertise of more than 40 highly specialized staff.

For further information, please visit our website: www.smaio.com

Listing market: Euronext Growth Paris
ISIN: FR0014005I80
Ticker: ALSMA

Disclaimer

This press release contains non-factual elements, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current vision and assumptions of the management of SMAIO. They incorporate known and unknown risks and uncertainties that could result in significant differences in results, profitability and expected events. In addition, SMAIO, its shareholders and its affiliates, directors, officers, counsels and employees have not verified the accuracy of, and make no representations or warranties about, statistical information or forecast information contained within this news release and that originates or is derived from third party sources or industry publications; these statistical data and forecast information are only used in this press release for information purposes. Finally, this press release may be drafted in French and in English. In the event of differences between the two texts, the English version will prevail.

Contacts

SMAIO
Philippe Roussouly
Chief Executive Officer
Renaut Fritsch
Chief Financial Officer
investors@smaio.com

NewCap
Dusan Oresansky/Thomas Cozzolino
Investor Relations
smaio@newcap.eu
Tel. : +33 (0)1 44 71 94 92

NewCap
Arthur Rouillé
Media Relations
smaio@newcap.eu
Tel.: +33 (0)1 44 71 00 15

SMAIO

BOURSE:ALSMA

Release Versions

Contacts

SMAIO
Philippe Roussouly
Chief Executive Officer
Renaut Fritsch
Chief Financial Officer
investors@smaio.com

NewCap
Dusan Oresansky/Thomas Cozzolino
Investor Relations
smaio@newcap.eu
Tel. : +33 (0)1 44 71 94 92

NewCap
Arthur Rouillé
Media Relations
smaio@newcap.eu
Tel.: +33 (0)1 44 71 00 15

More News From SMAIO

SMAIO Obtains €2.0m in Non-Dilutive Financing

DALLAS & LYON, France--(BUSINESS WIRE)--Regulatory News: SMAIO (Software, Machines and Adaptive Implants in Orthopaedics – Euronext Growth Paris, ISIN: FR0014005I80 / Ticker: ALSMA), a French-American player specialized in complex spine surgery, offering an integrated pre, intra, and post-operative solution based on a 3D planning software, adaptive implants and related services, today announced that it has obtained €2.0m in non-dilutive financing. A €1.0m loan from the European Union, the Auver...

SMAIO Successfully Continues Its Think Tanks Focused on Promoting Its Innovative Solutions in the United States

DALLAS & LYON, France--(BUSINESS WIRE)--Regulatory News: SMAIO (Software, Machines and Adaptative Implants in Orthopaedics – Euronext Growth Paris, ISIN: FR0014005I80 / Ticker: ALSMA), a French-American player specialized in complex spine surgery, offering an integrated pre, intra, and post-operative solution based on a 3D planning software, adaptive implants and related services, today announced the success of its fourth American Think Tank (exchange program on sagittal balance), held in New Y...

SMAIO Appoints Matthieu Ville as Chief Commercial Officer to Accelerate Commercialization and Strengthen Its Leadership in Spinal Realignment

DALLAS & LYON, France--(BUSINESS WIRE)--Regulatory News: SMAIO (Software, Machines and Adaptative Implants in Orthopaedics – Euronext Growth Paris, ISIN: FR0014005I80 / Ticker: ALSMA), a French-American company specialized in complex spine surgery with a global offer comprising software, adaptative implants and related services, today announced the appointment of Matthieu Ville as Chief Commercial Officer (CCO). A global business leader in MedTech commercialization Matthieu Ville is a French-Am...
Back to Newsroom